Education
About Us
Working with TipRanks
Follow Us
HilleVax, Inc (HLVX)
NASDAQ:HLVX
HLVX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.34 - $2.17
Previous CloseN/A
Volume43.09K
Average Volume (3M)678.74K
Market Cap
$103.29M
Enterprise Value-$36.28M
Total Cash (Recent Filing)$159.55M
Total Debt (Recent Filing)$23.54M
Price to Earnings (P/E)―
Beta1.62
Next Earnings
Nov 06, 2025EPS Estimate
-0.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.12
Shares Outstanding50,141,064
10 Day Avg. Volume554,205
30 Day Avg. Volume678,738
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap-0.35
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda0.54
Forecast
1Y Price Target
$2.00Price Target Upside-2.91% Downside
Rating ConsensusHold
Number of Analyst Covering0
Bulls Say, Bears Say
Bulls Say
Debt PositionThe company reported a cash balance of $171.4M as of Dec. 31 and maintains a net debt to total capital ratio of 0%.
Financial PerformanceThe company has approximately $159.5 million in cash and equivalents and has made significant reductions in operating expenses, positioning it to streamline its platform for future steps.
Vaccine DevelopmentThe norovirus opportunity remains tangible, with the potential to prevent moderate-to-severe acute gastroenteritis caused by norovirus infection, which results in significant global deaths annually.
Bears Say
Clinical TrialsThe Phase 2B NEST-IN1 trial for the HIL-214 vaccine did not achieve its primary or secondary endpoints, leading to the discontinuation of its development for infant patients.
Operational CostsHLVX reported 4Q OpEx of $36.1M which was +112% vs. analyst's $17M estimate.
Strategic UncertaintyNear-term uncertainty exists as the company explores paths forward for its norovirus vaccine development.
HilleVax, Inc News
HLVX FAQ
What was HilleVax, Inc’s price range in the past 12 months?
HilleVax, Inc lowest stock price was $1.34 and its highest was $2.17 in the past 12 months.
What is HilleVax, Inc’s market cap?
HilleVax, Inc’s market cap is $103.29M.
When is HilleVax, Inc’s upcoming earnings report date?
HilleVax, Inc’s upcoming earnings report date is Nov 06, 2025 which is in 74 days.
How were HilleVax, Inc’s earnings last quarter?
HilleVax, Inc released its earnings results on Aug 06, 2025. The company reported -$0.12 earnings per share for the quarter, the consensus estimate of -$0.12 by $0.
Is HilleVax, Inc overvalued?
According to Wall Street analysts HilleVax, Inc’s price is currently Overvalued.
Does HilleVax, Inc pay dividends?
HilleVax, Inc does not currently pay dividends.
What is HilleVax, Inc’s EPS estimate?
HilleVax, Inc’s EPS estimate is -0.12.
How many shares outstanding does HilleVax, Inc have?
HilleVax, Inc has 50,141,064 shares outstanding.
What happened to HilleVax, Inc’s price movement after its last earnings report?
HilleVax, Inc reported an EPS of -$0.12 in its last earnings report, expectations of -$0.12. Following the earnings report the stock price went up 0.488%.
Which hedge fund is a major shareholder of HilleVax, Inc?
Currently, no hedge funds are holding shares in HLVX
HilleVax, Inc Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$2.00 (-2.91% Downside)
$2.00 (-2.91% Downside)
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
3.25%
12-Months-Change
Fundamentals
Return on Equity
-40.31%
Trailing 12-Months
Asset Growth
-36.84%
Trailing 12-Months
Company Description
HilleVax, Inc
HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines. It is developing HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company is headquartered in Boston, Massachusetts.
Technical Analysis
Ownership Overview
2.36% Insiders
5.55% Mutual Funds
61.14% Other Institutional Investors
23.32% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---